scholarly journals An Observational Cohort Study on 194 Supraglottic Cancer Patients: Implications for Laser Surgery and Adjuvant Treatment

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 568
Author(s):  
Gerhard Dyckhoff ◽  
Rolf Warta ◽  
Christel Herold-Mende ◽  
Elisabeth Rudolph ◽  
Peter K. Plinkert ◽  
...  

Supraglottic laryngeal cancer is characterized by poor prognosis. In contrast, excellent outcomes have been published in early-stage supraglottic cancers after laser surgery in single-institutional series in centers of excellence. Are these results reproducible in the normal clinical practice of less specialized facilities? As part of an observational cohort study, the outcomes of 194 supraglottic cancer patients were assessed after treatment by larynx-preserving surgery (transoral laser microsurgery [TLM] or open partial laryngectomy [OPL]) or total laryngectomy (TL), with each having risk-adopted adjuvant treatment, or primary (chemo-)radiotherapy (pCRT or pRT). In early-stage supraglottic cancers, TLM achieved a 5-year overall survival (5-year OS) of 62.0%. No significant survival difference could be discerned between patients with and without adjuvant treatment (HR 1.47; 95% CI: 0.80 2.69). The comparison between pCRT and pRT patients suggests that CRT is more effective in supraglottic cancer. The 5-year OS rate achieved in our multiinstitutional setting is comparable to that reached in laser surgery centers of excellence (59.4–76.0%). According to our data and supported by the literature, adjuvant RT (aRT) is not sufficiently effective in supraglottic cancers. In case adjuvant therapy is indicated, adjuvant chemoradiation (aCRT) could be recommended.

2018 ◽  
Vol 29 ◽  
pp. viii234
Author(s):  
J.J. van Kleef ◽  
L.V. van de Poll-Franse ◽  
R.H. Verhoeven ◽  
M. Slingerland ◽  
J.P. Ruurda ◽  
...  

2018 ◽  
Vol 43 (1) ◽  
pp. 134-142 ◽  
Author(s):  
Saho Wada ◽  
Hironobu Inoguchi ◽  
Ryoichi Sadahiro ◽  
Yutaka J. Matsuoka ◽  
Yosuke Uchitomi ◽  
...  

Renal Failure ◽  
2014 ◽  
Vol 37 (1) ◽  
pp. 29-36 ◽  
Author(s):  
Jui-Hsiang Lin ◽  
Hung-Chieh Wu ◽  
Wen-Hung Huang ◽  
Chien-Lu Lu ◽  
Mei-Hua Cheng ◽  
...  

2019 ◽  
Vol 6 (3) ◽  
pp. 138
Author(s):  
Judith E. K. R. Hentzen ◽  
Laura Van Wijk ◽  
Carlijn I. Buis ◽  
Alain R. Viddeleer ◽  
Geertruida H. De Bock ◽  
...  

<p class="abstract"><strong>Background:</strong> Surgery-related muscle loss (SRML) occurs in at least one out of three cancer patients within one week after major surgery. Though, this important phenomenon has hardly been investigated.</p><p class="abstract"><strong>Methods:</strong> The MUSCLE POWER is a prospective, observational cohort study that investigates the presence, impact, and predictors for clinically relevant SRML in 178 cancer patients after major abdominal surgery using ultrasound measurements, squeeze and force measurements, and QoL questionnaires. Primary endpoint is the proportion of patients with clinically relevant SRML defined as ≥5% muscle loss within one week after surgery, measured by the cross-sectional area (CSA) of three different muscles: m. biceps brachii, m. rectus femoris, and m. vastus intermedius. Possible correlation with QoL and fatigue up to six months after surgery will be investigated. Daily physical activity during hospital stay will be monitored by a motility tracker, and protein intake will be monitored by a dietician. Possible predictors for clinically relevant SRML—consisting of age ≥65 years, preoperative diabetes, preoperative sarcopenia, major postoperative complications (Clavien-Dindo ≥III), insufficient physical activity, and insufficient postoperative protein intake—will be investigated with a multivariable logistic regression analyses with a backward stepwise approach. Variables with a <em>p</em>&lt;0.05 will be retrained in the final multivariable model.</p><p class="abstract"><strong>Discussion: </strong>The MUSCLE POWER investigates the presence and impact of clinically relevant SRML in cancer patients after major abdominal surgery. Crucial information regarding possible predictors for clinically relevant SRML can be used in future intervention studies to prevent postoperative muscle loss and subsequently improve postoperative outcome and QoL.</p><p><strong>Trial Registration: </strong>Medical Ethics Committee of the University Medical Center Groningen, the Netherlands (METc2018/361, version 3.0, January 21, 2019), and Netherlands Trial Register ([NTR], NTR NL7505, version 1.0, February 7, 2019).</p>


Sign in / Sign up

Export Citation Format

Share Document